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A B S T R A C T
Purpose: Lack of response to anti-epileptic drugs (AEDS) is considered a ‘‘red ﬂag’’ pointing to a diagnosis
of Psychogenic Nonepileptic Seizures (PNES). On the other hand, placebo effects are relevant in any
medical condition with a complex psychosocial component. We aimed to evaluate the presence and
frequency of a placebo response in patients with sole PNES and explore its impact on diagnostic delay.
Methods: We reviewed the medical records of 102 patients referred for video EEG monitoring and
diagnosed with PNES. Patients with PNES and epilepsy were excluded. The response to AEDs was
analyzed according to patients’ reports and medical records. Patients were classiﬁed, according to the
response to AEDs, in two groups: responders (patients achieving remission) and non-responders. Then,
we compared the diagnostic delay from the ﬁrst event to the ﬁnal diagnosis between these groups.
Results: Forty-seven patients (79.7%) with sole PNES who were using AEDs were identiﬁed. Twenty-two
patients (46.8%) had reported complete or partial remission of PNES with mean response duration of 7.2
months (SD + 9.6 months). The time delay of the diagnosis in the AED responder group was 10.6 years;
the delay in non-responders was 5.6 years (p = 0.035).
Conclusion: Patients with sole PNES receiving AEDs can go into PNES remission. A favorable response to
AEDs is likely to be interpreted as supporting a diagnosis of epilepsy and is associated with diagnostic
delay. Physicians should bear in mind that patients with PNES may be particularly vulnerable to placebo
effects.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The early and accurate recognition of Psychogenic Nonepileptic
Seizures (PNES) and the differentiation of this disorder from
epileptic seizures (ES) are of paramount importance. Extensive
work has been conducted to identify the factors that might
facilitate this diagnosis and consequent referral to video-EEG
monitoring to decrease the delay in diagnosis.1
Most patients with PNES are presumed to have epilepsy and are
treated with anti-epileptic drugs (AEDs).2,3 A lack of response to
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tertiary epilepsy centers.4
Placebo effects are signiﬁcant in all medical disorders with a
complex psychosocial component.5,6 Little published data exists
regarding the placebo response to AED in PNES, but one study7
suggested that placebo response occurs in 43% of all patients.
This observational retrospective cohort study was conducted in
a tertiary care center for epilepsy treatment and sought to
accomplish the following: (i) document the presence and
frequency of a placebo response characterized by a decrease in
PNES following AED administration; and (ii) identify the possible
effects of such decrease on diagnostic delay.
2. Methods
2.1. Patients
The studied population was selected from a consecutive series
of 102 patients who were diagnosed with PNES. All patients wereserved.
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video-EEG monitoring.
Patients with current or previous history of epilepsy were
excluded. The criteria for the diagnosis of epilepsy were in
agreement with previous work.1,6 We did not consider the
following patients with PNES: (i) those without video-EEG
conﬁrmation, including patients with reliable home-videos or
PNES that were witnessed by one of the authors and; (ii) those with
unclear time of PNES onset.
Thirty-ﬁve patients (34.3%) were excluded due to diagnoses of
epilepsy and PNES, and nine (8.8%) patients were excluded due to
an unclear time of PNES onset.
Fifty-nine patients (43 female [72.9%]; mean age of 35.12 years
[SD  10.74]) who fulﬁlled the diagnostic criteria were diagnosed
with PNES alone. Twelve patients were not using AEDs and were
excluded from this analysis.
2.2. Methods
The PNES frequency was evaluated based on two measures: the
patients’ medical ﬁle, and a direct interview during video-EEG.
Seizure diaries were evaluated by the patients’ doctors and
were reported in the patients’ medical ﬁles at the times of their
medical appointments. These ﬁles were retrospectively assessed
during video-EEG monitoring by the authors.
The patients and their families were directly interviewed
during video-EEG monitoring. The information obtained during the
interview was required to be consistent with the results of the
medical chart revision. In cases of doubt, the patient and family
were directly questioned. Only patients who fulﬁlled this criterion
were included.
Patients with PNES alone were categorized, according to the
response to AEDs, in two groups: responders (patients who
achieved PNES remission) and no responders (patients who
experienced no improvement).
Remission was considered partial (>50%) or complete based on
a comparison to the baseline condition prior to AED administra-
tion. The time of remission was also documented for each patient
based on the medical ﬁle revisions.
Additionally, we evaluated the diagnostic delay between the
ﬁrst event and the ﬁnal diagnosis during the video-EEG.
2.3. Statistical analysis
First, the clinical and demographic variables were compared
between the groups using Student’s t-test for continuous data. TheTable 1
Characteristics of patients with PNES.
Responders [22/47 (46.8%)] No
Mean age 34.91 (SD 11.95) 34
Gender (females) 19/22 (86.4%) 14
Polytherapy 16 (72.7%) 18
Mean age of onset 26.77 years 29
(SD 11.75) (SD
Mean diagnostic delay 10.59 years 5.6
(SD 10.10) (SD
PNES semiological classiﬁcation Major motor M
12 (54.5%) 15
Anxiety disorders 3 (13.6%) 5 (
Mood disorders 13 (59.1%) 13
Use of antipsychotic drugs 3 (13.6%) 3 (
Use of antidepressants 9 (40.9%) 10
Bold indicates signiﬁcance.
* Fisher’s exact test.
a Student’s t test.
b chi2 test.chi-square and Fisher’s exact tests were used for categorical data.
The level of signiﬁcance was set at 5%.
3. Results
3.1. Remission of PNES
Forty-seven patients (79.7%) with sole PNES received AED
treatment. Thirty-three women (70.2%) ranging in age from 18 to
55 years (mean age of 36.7 years) comprised the study group.
Fourteen patients (29.8%) were receiving monotherapy, and 33
(70.2%) were receiving polytherapy. The AEDs that were used were
the following: carbamazepine (35 [74.5%]); valproate (19 [40.4%]);
phenytoin (11 [23.4%]); phenobarbital (10 [21.3%]); topiramate (7
[14. 9%]); and lamotrigine (6 [12.8%]).
Five (10.6%) patients experienced complete remission, and 17
(36.2%) reported decrease in the frequency of PNES following AED
administration (i.e., after the introduction and/or titration of an
AED). The period of remission ranged from 2 months to 4 years
(mean of 7.2 months; median of 4 months; SD  9.6 months).
None of the patients reported increase in seizures following
AED administration. Five patients who experienced partial
remission also reported changes in event semiology (i.e., the
seizures were less intense and shorter than usual).
Twenty-ﬁve (53.2%) patients reported no improvement due to
AEDs.
The clinical characteristics of these groups were similar with
the exception of the female predominance (p = 0.023) among the
group that experienced PNES remission (Table 1).
3.2. Duration of the delay to diagnosis
The duration of the diagnostic delay was 10.59 years among the
AED responders (SD  10.10) and 5.60 years (SD  5.07) among the
non-responders (Fig. 1).
The mean diagnostic delay was considerably longer among the
responders than the non-responder PNES patients (p = 0.035).
The patients who were receiving polytherapy reported a greater
number of side effects. Six patients (6.4%) reported intoxication
characterized by vertigo, drowsiness and ataxia. Nineteen (40.4%)
patients (40% [10/25] among the non-responders and 40.9% [9/22]
among the responders) reported side effects that warranted dose
reductions or the use of another AED.
The patients who exhibited decrease in PNES did not exhibited a
greater number of side effects (p = 0.956).n-responders [25/47 (53.2%)] Statistic P-value
.56 (SD 10.09) t = 0.398 (45 df)a 0.693
/25 (56.0%) x2 = 5.159 (1 df)b 0.023
 (72.0%) x2 = 0.003 (1 df)b 0.956
.24 years t = 0.754 (45 df)a 0.455
 10.70)
0 years t = 2.180 (45 df)a 0.035
 5.07)
ajor motor x2 = 0.142 (1 df)b 0.706
 (60.0%)
20.0%) * 0.706
 (52.0%) x2 = 0.238 (1 df)a 0.626
12.0%) * 1000
 (40.0%) x2 = 0.004 (1 df)a 0.949
Fig. 1. Time delay for diagnosis in group I (placebo response) and group 2 (non-
responders).
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The placebo effect is a frequently observed phenomenon that
has been described in different conditions.5–7 In patients with
PNES, the placebo response is characterized by a remission due to
AEDs, which reinforces the diagnosis of epilepsy and is associated
with important economic and social costs.8 Therefore, the authors
believe that the placebo response deserves special attention in
PNES.
In this retrospective observational study, we observed that
nearly 80% of the patients with PNES without epilepsy received
AEDs, which reemphasizes that patients with PNES are treated as
patients with refractory epilepsy.2
In a previous work, Oto et al.7 reported that 43% of their patients
experienced improvement in PNES frequency after initiating AEDs.
Our ﬁndings not only corroborate this high rate of placebo
response but also show that the placebo effect in PNES is greater
(43–46.8%) than those that are typically documented in other
disorders (30%).5–7 In our group, the durations of PNES remission
were as long as 4 years. Some of our patients also reported changes
in semiology that were similar to those that have been described
by patients with epilepsy.
There is evidence that patients with PNES are suggestible,1 and
this suggestibility might have contributed to an enhanced
susceptibility to the placebo response among our patients.
However, mood-stabilizing effects might have contributed in
some cases.
De Timary et al.9 emphasized that diagnosis of epilepsy should
be reconsidered for patients with seizures that do not respond to
AEDs. Moreover, Davis10 suggested that lack of response to AEDs is
a major predictor of PNES prior to video-EEG. It seems reasonable
to state that the placebo effect has been frequently neglected in
PNES. A lack of response to AEDs remains a common-knowledge
red ﬂag for the diagnosis of PNES4 among neurologists and
psychiatrists.
In a previous study that was conducted with a large sample of
102 Brazilian patients, we documented a diagnostic delay of 7.8
years.11 In the current study, the patients who experienced PNES
remission had a mean diagnostic delay of 10.6 years, and the otherpatients had a mean delay of 5.6 years. These ﬁndings demonstrate
the clinical effect of this placebo effect on diagnosis.
One point that should be addressed is that the responders and
non-responders did not differ in the majority of demographic and
clinical aspects. The female predominance among the placebo
group might have been incidental and due to the small sample size
or due to a gender-linked difference in the effects of modeling on
psychogenic symptoms as has previously been reported.12
Multiple patient factors are associated with longer delays to
diagnosis,3 and such delays obviously cannot be explained by one
single factor. AED treatment has previously been shown to be one
of these factors.3 It is possible that the response to AED treatment
might have played a role in the former series.
The retrospective nature of this study was a major limitation to
our ability to precisely determine the PNES frequency. Therefore,
most of the information obtained was based in the patients’ and
doctors’ perceptions. Precise quantitative data were not attainable
with this study design. Another issue was the small sample size of
each group. A prospective study with larger sample sizes is
necessary to conﬁrm these results and to delineate the differences
between these groups.
In conclusion, patients with PNES without epilepsy can exhibit a
decrease in PNES frequency due to a placebo effect. A favorable
response to AEDs favors the diagnosis of epilepsy and postpones
the diagnosis of PNES. Thus, neurologists and psychiatrists need to
be aware that this group of patients is highly vulnerable to placebo
effects and thus a good response to AEDs cannot be used as an
isolated sign in the diagnosis of PNES.
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